已发表论文

血清外胚层 miR-125b 是肝细胞癌的新型预后标志物

 

Authors Liu W, Hu J, Zhou K, Chen F, Wang Z, Liao B, Dai Z, Cao Y, Fan J, Zhou J

Received 20 April 2017

Accepted for publication 13 June 2017

Published 1 August 2017 Volume 2017:10 Pages 3843—3851

DOI https://doi.org/10.2147/OTT.S140062

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Abstract: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted from serum samples collected from two independent cohorts: cohort 1: HCC (n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2: HCC (n=128). We found that miR-125b levels were remarkably increased in exosomes compared to those in serum from patients with CHB, LC, and HCC (<0.01, respectively). However, miR-125b levels in exosomes and the serum from HCC patients were inferior to that of CHB (<0.01 and =0.06) and LC patients (<0.01 for all). Additionally, miR-125b levels in exosomes were associated with tumor number (=0.02), encapsulation (<0.01), and TNM stage (<0.01). Kaplan–Meier analysis indicated that HCC patients with lower exosomal miR-125b levels showed reduced time to recurrence (TTR) (<0.01) and overall survival (OS) (<0.01). Furthermore, multivariate analysis revealed that miR-125b level in exosomes, but not in serum, was an independent predictive factor for TTR (<0.001) and OS (=0.011). Exosomal miR-125b levels predicted the recurrence and survival of HCC patients with an area under the ROC curve of 0.739 (83.0% sensitivity and 67.9% specificity) and 0.702 (82.5% sensitivity and 53.4% specificity). In conclusion, exosomal miR-125b could serve as a promising prognostic marker for HCC.
Keywords: exosome, miR-125b, hepatocellular carcinoma, prognosis, serum